Recent Activity

Loading...

ATXS

Astria Therapeutics, Inc. · NASDAQ

Performance

-6.19%

1W

-14.05%

1M

-31.71%

3M

+111.06%

6M

+24.22%

YTD

-22.82%

1Y

Profile

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

Investment Analysis Report: ATXS

Overview

ATXS is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $763.68 million. The company's financial data provides insights into its valuation, financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, and capital e...

See more ...

Technical Analysis of ATXS 2024-05-10

Overview:

In analyzing the technical indicators for ATXS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for investors and...

See more ...

Recent News & Updates